


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Dec-2022
Document Type: USP Monographs
DocId: GUID-295AFF3A-283C-44FF-BF46-3582678AC343_2_en-US
DOI: https://doi.org/10.31003/USPNF_M3453_02_01
DOI Ref: 2370t

© 2025 USPC
Do not distribute

Add the following:

^Etravirine



$C_{20}H_{15}BrN_6O$ 435.29
Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-;
4-({6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl}oxy)-3,5-dimethyl-benzonitrile CAS RN®: 269055-15-4; UNII: 0C50HW4F01.

DEFINITION
Etravirine contains NLT 98.0% and NMT 102.0% of etravirine ($C_{20}H_{15}BrN_6O$), calculated on the anhydrous and solvent-free basis.

- IDENTIFICATION**
- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197K or 197A
 - **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

- ASSAY**
- **PROCEDURE**
Protect solutions containing etravirine from light.
Buffer: 10 mM [ammonium formate](#) in [water](#)
Diluent: [Acetonitrile](#) and *Buffer* (10:9, v/v)
Solution A: 50 mM [formic acid](#) in *Buffer*
Solution B: [Acetonitrile](#)
Solution C: [Methanol](#)
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)	Solution C (%)
0	60	30	10
35	0	0	100
37	60	30	10
45	60	30	10

Standard stock solution: 2.0 mg/mL of [USP Etravirine RS](#) in [1-methyl-2-pyrrolidone](#)
Standard solution: 0.10 mg/mL of [USP Etravirine RS](#) from the *Standard stock solution* in *Diluent*
Sample stock solution: 2.0 mg/mL of Etravirine in [1-methyl-2-pyrrolidone](#)

Sample solution: 0.10 mg/mL of Etravirine from the *Sample stock solution* in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

Mode: LC

Detector: UV 310 nm

Column: 3.0-mm × 15-cm; 5-μm packing [L1](#)

Column temperature: 35°

Flow rate: 0.6 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of etravirine (C₂₀H₁₅BrN₆O) in the portion of Etravirine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of etravirine from the *Sample solution*

r_S = peak response of etravirine from the *Standard solution*

C_S = concentration of [USP Etravirine RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Etravirine in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0%, on the anhydrous and solvent-free basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

Protect solutions containing etravirine from light.

Buffer, Diluent, Solution A, Solution B, Solution C, Mobile phase, Standard stock solution, Standard solution, Sample stock solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

System suitability solution: 0.10 mg/mL of [USP Etravirine System Suitability Mixture RS](#) prepared as follows. Transfer a suitable amount of [USP Etravirine System Suitability Mixture RS](#) to a suitable volumetric flask and dissolve in 10% of the total volume of [1-methyl-2-pyrrolidone](#). Dilute with *Diluent* to volume.

Sensitivity solution: 0.05 μg/mL of [USP Etravirine RS](#) from the *Standard solution* in *Diluent*

System suitability

Samples: *Standard solution*, *System suitability solution*, and *Sensitivity solution*

[NOTE—The relative retention times for etravirine amino analog and desbromoetravirine in relation to etravirine are 0.66 and 0.73, respectively.]

Suitability requirements

Resolution: NLT 4.3 between etravirine amino analog and desbromoetravirine, *System suitability solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of any individual impurity in the portion of Etravirine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of any individual impurity from the *Sample solution*

r_S = peak response of etravirine from the *Standard solution*

C_s = concentration of [USP Etravirine RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Etravirine in the *Sample solution* (mg/mL)

F = relative response factor (see [Table 2](#))

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Etravirine amino analog ^{a,b}	0.66	1.3	—
Desbromoetravirine ^{c,b}	0.73	1.0	—
Etravirine	1.0	1.0	—
Etravirine butanamide analog ^d	1.08	0.77	0.30
Etravirine dimer ^e	1.41	0.86	0.50
Any individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	1.0

^a 4-[(4-Amino-5-bromo-6-chloropyrimidin-2-yl)amino]benzonitrile.

^b For peak identification purpose. If present, these impurities are covered under acceptance criteria for any individual unspecified impurity.

^c 4-[(6-Amino-2-[(4-cyanophenyl)amino]pyrimidin-4-yl)oxy]-3,5-dimethylbenzonitrile.

^d 4-[(5-Bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]pyrimidin-4-yl)(methyl)amino]butanamide.

^e 4,4'-[5-Bromo-2-[(4-cyanophenyl)amino]pyrimidine-4,6-diyl]bis(oxy)}bis(3,5-dimethylbenzonitrile).

SPECIFIC TESTS

- **WATER DETERMINATION** (921), [Method I](#), [Method Ia](#): NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, and store at room temperature.

- **USP REFERENCE STANDARDS** (11).

[USP Etravirine RS](#)

[USP Etravirine System Suitability Mixture RS](#) ▲ (USP 1-Dec-2022)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ETRAVIRINE	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 47(3)

Current DocID: GUID-295AFF3A-283C-44FF-BF46-3582678AC343_2_en-US

DOI: https://doi.org/10.31003/USPNF_M3453_02_01

OFFICIAL